Spread of a disease inside a body
POPULARITY
Categories
310 episodes with metastatic
51 episodes with metastatic
72 episodes with metastatic
21 episodes with metastatic
38 episodes with metastatic
24 episodes with metastatic
16 episodes with metastatic
30 episodes with metastatic
19 episodes with metastatic
15 episodes with metastatic
27 episodes with metastatic
15 episodes with metastatic
15 episodes with metastatic
22 episodes with metastatic
14 episodes with metastatic
20 episodes with metastatic
8 episodes with metastatic
11 episodes with metastatic
12 episodes with metastatic
10 episodes with metastatic
11 episodes with metastatic
11 episodes with metastatic
13 episodes with metastatic
11 episodes with metastatic
11 episodes with metastatic
7 episodes with metastatic
8 episodes with metastatic
8 episodes with metastatic
11 episodes with metastatic
12 episodes with metastatic
15 episodes with metastatic
16 episodes with metastatic
5 episodes with metastatic
8 episodes with metastatic
7 episodes with metastatic
10 episodes with metastatic
8 episodes with metastatic
9 episodes with metastatic
6 episodes with metastatic
9 episodes with metastatic
6 episodes with metastatic
11 episodes with metastatic
3 episodes with metastatic
7 episodes with metastatic
5 episodes with metastatic
4 episodes with metastatic
7 episodes with metastatic
6 episodes with metastatic
10 episodes with metastatic
5 episodes with metastatic
4 episodes with metastatic
7 episodes with metastatic
6 episodes with metastatic
12 episodes with metastatic
If you're struggling with issues affecting your sexuality, you're not alone. Sex and intimacy can be difficult for many women after a breast cancer diagnosis. Joining us today is Amy Rowan, a Certified Clinical Sexologist and Intimacy Coach. She's known as the Suburban Sexologist because she is just like so many of you – a busy, working mom and breast cancer survivor who just gets it. She makes talking about sex seem like the most comfortable thing in the world and she is here today to acknowledge just how hard intimacy after breast cancer can be and to give us some tips on how to deal with emotions and regain intimacy after treatment.
Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed
Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed
This PER® Spectives™ featured podcast reviews the 22nd Annual Winter Lung Cancer Conference® held in January/February 2025. Multiple successive generations of ALK inhibitors have provided increasing benefits as first-line treatment for the thousands of patients with non-small cell lung cancer (NSCLC) that harbors rearrangements or mutations in the ALK gene. This program focuses on the practical aspects of managing patients with ALK-positive advanced or metastatic NSCLC, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-chemotherapy-options-in-metastatic-pdac/33136/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/first-line-chemotherapy-options-in-metastatic-pdac/33135/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Brett Heins went through breast cancer in her late 30s. Kristin Goodman was in her early 40s when she was diagnosed. Both women are well below the average age at diagnosis – 62 – leading them to wonder what caused their cancer to develop. A growing body of research shows lifestyle choices – everything from drinking alcohol to following a healthy diet – influences one's risk of breast cancer.
Featuring an interview with Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:22) CME information and select publications
Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.
Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:31) CME information and select publications
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers.This episode will cover the topic of Metastatic Disease of Extremity, from our Pathology section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Everyone is at risk of breast cancer. Some are more at risk than others due to hereditary factors – such as a family history of cancers – and lifestyle choices that affect our overall health. Knowing your risk of breast cancer can help you decide what steps to take to lower your risk. Joining me today is Dr. Jennifer Ligibel, a Susan G. Komen Scholar and Komen grantee, Professor of Medicine at Harvard Medical School, Senior Physician at the Dana-Farber Cancer Institute and an expert on the impact of lifestyle factors, cancer risk and outcomes. Through more than a dozen lifestyle intervention trials, Dr. Ligibel has evaluated the impact of exercise, weight loss, fitness, body composition and quality of life in cancer patients and survivors.
Today, we discuss the role of triplet therapy (ie, chemotherapy and androgen receptor signalling inhibitor and ADT) in high-volume metastatic hormone-sensitive prostate cancer and whether darolutamide is equivalent to the other androgen receptor signalling inhibitors in the castrate-sensitive space. Two good trials, and as always, some interesting discussion points.Studies discussed in the episode:ARASENSARANOTEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Just before her 38th birthday, Lauren Yerkes learned she had breast cancer. Genetic testing would reveal she had the BRCA2 inherited gene mutation that made her at higher risk of developing breast and ovarian cancers. Her experience made her want to educate people about inherited genetic mutations because she had no idea at the time that she was at risk. Lauren is here today to share her story, the preventative measures she has taken for her health and how she is giving back to the breast cancer community.
Title: Controversies in Neurosurgery: Carbon Fiber versus Titanium in Metastatic Spine Cancer Guest Faculty: Ilya Laufer Hosts: Brian Gantwerker, MD and W. Christopher Newman, MD In this episode we will discuss the use of carbon fiber implants for spinal instrumentation in patients with metastatic spine cancer, covering the indications, benefits, and limitations. We also will discuss how to incorporate these implants into your practice.
The rise and rise of Androgen Receptor Pathway (or Signalling) Inhibitors has changed the world of metastatic prostate cancer forever. What was once a cancer with a finite number of treatment options has flourished into a chasm of therapies, many more effective and less toxic than their therapeutic grandparents.Studies discussed in the episode:ARCHESENZAMETFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Like the seeds of a dandelion drift on the wind and land other places, cancer can spread under the right conditions. How does cancer spread and why does it happen? We tackle these questions in this episode in our series “Everything you always wanted to know about cancer, but didn't have anyone to ask.” https://bit.ly/440dQKoIn This Episode:3:44 - Road Trip: Missouri and Recipe for Gooey Butter Cake5:22 - What is Your Life's Resume? A Short Guide to a Happy Life8:10 - What Makes Cancer Spread? (Metastasize)11:33 - Why Does Metastasis Happen?13:58 - Where Does Cancer Tend to Spread To?16:02 - Discussion About Metastatic Cancer17:42 - Discussion - How Do You Find Cancer?23:26 - What's Left of Me: Poems of a Dead Soul24:12 - OutroSimply put, metastasis is when the cancer moves from the original organ to another part of the body. The goal of treating metastatic cancer is to control it by stopping or slowing its growth. Some people can live for years with metastatic cancer that is well-controlled. The treatment depends on the type of primary cancer, where it has spread, previous cancer treatments, and general health.Cancer researchers, at the most basic level, focus their energy on what makes cancer cells start in the first place and what makes it metastasize. We've been talking the last few weeks about the basic aspects of cancer and this week we are going to talk about cancer cells going rogue and moving through the body. This is called metastasis, or stage 4 cancer. #cancer #metastaticcancer #metastasis #stage4 #stageIV #stupidcancer #cancersucks #healtheducation #publichealth #everyonedies #everydayisagift #palliativecare #cancerresources #cancereducation Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org
Today, we're honored to share the story of Nancy Pickett, a woman whose breast cancer journey is not just her own — it's part of a long family history. Nancy is the ninth person in her family to be diagnosed with breast cancer, making her path one of both personal resilience and advocacy. As we celebrate Women's History Month, we recognize that every woman's breast cancer journey is unique. That's why personalized care is so important — ensuring that every patient gets the right support, resources and treatment for their specific needs.
Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of prostate cancer with Dr. Alan Bryce, Chief Clinical Officer and GU Medical Oncologist from City of Hope. In this episode, we explore: • The treatment paradigm for early-stage prostate cancer, including the role of active surveillance and the use of abiraterone based on the STAMPEDE trial. • The importance of understanding risk factors and treatment options for low, intermediate, and high-risk patients. • The implications of PET-PSMA imaging versus conventional CT modalities in staging and treatment decisions. • The management of biochemical recurrent disease and the significance of PSA doubling time in treatment planning. • The role of PARP inhibitors in patients with HRR mutations and the nuances of selecting appropriate therapies. • Strategies for managing metastatic disease, including the use of Lutetium-177 (Pluvicto) and cabazitaxel. Dr. Bryce provides a masterclass on navigating the complexities of prostate cancer treatment, emphasizing the need to balance between over-treatment in early disease and under-treatment in metastatic cases. YouTube: https://youtu.be/Zfu-yGmH0rg Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ If you find this episode helpful, please share it with your colleagues and leave us a review! Don't forget to check out our other episodes in the GU treatment algorithm series, including discussions on renal cell carcinoma and bladder cancer.
We are so excited to welcome back Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at MSK in NYC, and co-host of the podcast 'The Good News About Cancer'. This episode will cover metastatic prostate cancer including board review pearls & key toxicities of treatments, upcoming exciting research in PCa, and advice for trainees/early career faculty.
In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Sebastian Stintzing, Head of Department of Medicine, Division of Hematology, Oncology, and Cancer Immunology, Charité - Universitäetsmedizin Berlin, Germany. They discuss the most promising developments in gastrointestinal oncology, with particular focus on the role of personalised medicine in metastatic colorectal cancer treatment. Timestamps: 00:00 – Introduction 03:04 – Impactful developments in gastrointestinal oncology 08:53 – Issues with funding clinical trials 14:17 – Designing trials and the importance of patient advocacy 17:11 – Translational biomarker programs 19:58 – Treatment strategies for RAS wild-type tumours 22:28 – The FIRE-4.5 study on mutant metastatic colorectal cancer 29:50 – Genetic profiling and epigenomics 33:12 – Precision medicine and immune oncology in GI cancers 34:52 – Colorectal cancer in younger adults 34:54 – Raising awareness for early screening of GI cancers
Breast cancer risk looks different for everyone. Our guests today have an inherited genetic mutation that increased their risk of breast cancer. Without knowing it, they may have passed this gene onto their children. Genetic mutations can increase risk of breast and ovarian cancers in women, and prostate cancer in men. About 10% of breast cancers are genetic – knowing if you have a gene mutation can help you take steps to lower your risk. It can also cause fear and anxieties and force tough conversations with family members about their genes and cancer risk. Shanise Pearce learned in 2020 that she has two inherited gene mutations and was diagnosed with breast cancer in 2023. She also has two daughters. Natalie Gutierrez was diagnosed with breast cancer in 2023 and learned afterward that she carries an inherited gene mutation. She has twin sons. Shanise and Natalie are both living with no evidence of breast cancer and have turned their attention to supporting their children and helping them navigate their cancer risk.
Welcome to Season 2 of the Orthobullets Podcast. Today's show is Core, where we review Core Knowledge for Orthopaedic Surgeons. This episode will cover the topic of Metastatic Disease of Extremity, from our Pathology section at Orthobullets.com. Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
This week, we prematurely dive into prostate cancer (one breast episode remaining - whoops!), where we explore the early pivotal trials, including the role of abiraterone in metastatic hormone-sensitive prostate cancer and the use of docetaxel in high and low-volume prostate cancer.Studies discussed in the episode:LATITUDESTAMPEDEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Send us a textCancer staging is very important to guide treatment decisions and eligibility in studies. When an oncologist delivers a diagnosis it will include stage, but what does that mean? After an agonizing period of tests, waits for results, and finally an answer, many people go numb as soon as they hear the word "cancer" and fail to ask for clarification about terminology. Learn what you need to know to be an active participant in your care. Show Notes: https://bit.ly/41q519XIn this Episode:01:45 - Recipe: Alabama Lane Cake, featured in "To Kill a Mockingbird"03:13 - A Short Guide to a Happy Life by Anna Quindlen07:23 - What You Need to Know About Cancer Staging09:48 - The Exceptions to Staging11:02 - Understanding Staging with a Stomach Cancer Example18:11 - Cancer Staging Sub-Categories20:44 - TNM Categories24:15 - Discussion - Thoughts About Stage 430:22 - A Letter Attributed to David Bowie, Who Died from Liver Cancer32:57 - OutroWhat is Cancer Staging?Our focus today is to help you understand the cancer staging system. The stage of disease measures if the cancer has spread, and how far is has spread from where it started. Cancer staging is a way to communicate the extent of cancer in the body so that everyone involved is speaking the same language.Cancer Staging Example: Stomach CancerDr. Matzo used stomach cancer as a way to understand staging. Visit our show notes for an image and detailed explanations.Marianne also shared about cancer sub-categories, such as 1a, 2c, etc. This further refines the definition of how far the cancer has spread.Cancer Staging with TNM CategoriesThe Tumor-Node-Metastasis notation is an even more refined way to define the extent of cancer spread. TNM helps to establish the anatomic extent of the disease, and the combination of the 3 factors can define the overall tumor stage. This method allows for simplification, with cancers staged from I-IV, with stage IV being the most severe stage. Related Episodes:S5E45: Why Does Cancer Exist? Empower Yourself With UnderstandingS5E46: “Why Do I Have Cancer?” Kismet, Chastisement or Coincidence?S5E47: MythBusters – Cancer Edition; Clarifying Common Cancer Myths & MisconceptionsS5E48: How to Read a CT Scan Report – Learn the Sections Relevant to Your DiagnosisS5E49: Are there Miracle Cures for Cancer? With Dr. Jeanna FordS4E46: What You Need to Know about Stomach Cancer – Part 1S4E47: What You Need To Know About Stomach Cancer, Part 2Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org
In our exclusive interview, Dr Uboha discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 RATIONALE-306 trial (NCT03783442), and considerations for integrating this agent into the ESCC treatment paradigm.
In 2017 Sharon was diagnosed with ovarian cancer. She underwent a radical surgery and chemotherapy. She had a recurrence in late 2019 and after more chemotherapy was told she had widespread bone metastacies. At that point, Sharon stopped all conventional treatment and opted for mistletoe and a functional medicine approach. She has been NED since late 2020 and continues with functional medicine and mistletoe. Today Sharon lives in London, is a clinical nurse and a trained functional medicine practitioner. She is passionate about raising awareness around ovarian cancer and functional medicine. To learn more about Sharon and her healing journey visit - sharondobbs-richards.com or email her directly at sharon@sharondobbs-richards.com. You can purchase Sharon's novel called, How To Kill Your Gynecologist, on Amazon Follow Sharon on LinkedIn To find your Functional Medicine practitioner visit www.ifm.org Learn more about Sharon's breathwork practitioner at sophietrew.com ________________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here. To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook Instagram YouTube ______________ Thank you to our friends from The Healing Oasis for sponsoring this episode of the podcast. The Healing Oasis is a first of its kind in beautiful British Columbia, Canada where we encourage the body to heal from cancer using alternative therapies & cancer fighting meals at a wellness retreat center in nature. Our top naturopathic cancer doctor will prescribe a protocol tailored specifically for you. There's no place quite like it. Start your healing journey today! Learn More about The Healing Oasis by visiting these links: Website Testimonials Video Overview
Today's episode is focusing on what you need to know regarding metastatic colon cancer. This will include the need to know about molecular studies, treatment, and surgery for oligometastatic disease. There has been three breakthroughs since we last covered this topic in the treatment of metastatic CRC based on molecular findings that we will go over today.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZXT865. CME/MOC/AAPA/IPCE credit will be available until March 13, 2026.Precision Medicine Crafts a New Story for Metastatic Prostate Cancer: The Next Act of Therapeutic Intensification With AKT Inhibition and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
Prostate cancer is the most common nonskin cancer in men in the US and the second most common cancer in men worldwide. Author R. Bruce Montgomery, MD, of the University of Washington joins JAMA Senior Editor Karen Lasser, MD, MPH, to discuss the current evidence regarding the epidemiology, diagnosis, and management of localized and metastatic prostate cancer. Related Content: Prostate Cancer
Welcome to the Real Pink Podcast by Susan G. Komen. I'm Adam Walker, and each week we take a look at the stories of real people affected by breast cancer. Today, I'm thrilled to introduce our special guest host, three-time Emmy Award winner, author and breast cancer survivor Gaby Natale! Gaby is a proud Komen Ambassador, using her voice to educate, empower and uplift communities—especially the Latino community—about the importance of breast health. She'll be leading today's conversation with two of the talented actors and producers behind the film “Las Tres Sisters,” Valeria Maldonado and Marta Cross. This powerful film explores family, resilience and the conversations we need to have about our breast health.
Dr Kaklamani discusses the mechanism of action of inavolisib, the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm, and considerations for early biomarker testing in patients with breast cancer.
As our breast cancer journey comes close to finishing, it was always the destiny of your cohost's on Oncology for the Inquisitive Mind to talk about HER2-positive breast cancer. This week, we target both antibody-drug conjugate therapy and targeted therapy (trastuzumab deruxtecan and pertuzumab). While HER2-positive cancer's survival is one of the best for metastatic disease, this was not always the case. Studies discussed in the episode:DESTINY 03 CLEOPATRA TrialFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Is there a way to treat liver metastasis secondary to uveal melanoma without introducing systemic, treatment-related toxicity? Dr. Altan Ahmed (interventional radiologist at Moffitt Cancer Center) and Dr. Sid Padia (interventional radiologist at UCLA) join guest-host Dr. Kavi Krishnasamy to discuss HEPZATO, a novel device-based treatment for liver metastases from uveal melanoma. --- This podcast is supported by: RADPAD® Radiation Protection https://www.radpad.com/ --- SYNPOSIS Dr. Ahmed and Dr. Padia begin by exploring the design and setup of the HEPZATO clinical trials, while also speaking on patient selection criteria. The doctors then talk through the technical aspects of the intervention. After covering workflow and considerations related to procedure timing and coordination, the doctors go on to discuss drug dosing and optimizing treatment cycles. The episode concludes with current gaps in literature, current and future research aims, and potential future applications of the HEPZATO modality in treating other malignancies such as colorectal cancer. --- TIMESTAMPS 00:00 - Introduction 05:40 - Patient Selection Criteria 09:49 - Workflow 19:17 - Procedure Timing and Coordination 29:39 - Challenges and Considerations in Drug Dosing 32:39 - Optimizing Treatment Cycles and Patient Response 37:56 - Managing Post-Treatment and Adverse Effects 43:43 - Future Research and Gaps in Current Interventions 50:45 - Exploring New Applications for PHP Therapy 55:02 - Conclusion --- RESOURCES Hepzato: https://hepzatokit.com/ FOCUS Trial - Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study: https://pubmed.ncbi.nlm.nih.gov/38704501/ FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A): https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.9510 Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial: https://pubmed.ncbi.nlm.nih.gov/36624292/ Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma: https://pmc.ncbi.nlm.nih.gov/articles/PMC11010739/ Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC7801354/ Southampton group - Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma: https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/ Leiden group - Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases: https://pubmed.ncbi.nlm.nih.gov/38587534/
It is Triple Negative Breast Cancer Day – an annual opportunity to bring more awareness to this aggressive type of breast cancer that is difficult to treat because it lacks an estrogen, progesterone and HER2 receptor. It primarily affects younger women and Black women and can spread quickly and be deadly if left untreated for too long. Treatment for TNBC used to include the toughest forms of chemotherapy, with debilitating side effects – but we've come a long way in how we treat patients with Triple Negative Breast Cancer so their outcomes are better. Today, we are speaking with Dr. Heather McArthur of UT Southwestern. She is a former Susan G. Komen grantee, Professor and the Komen Distinguished Chair in Clinical Breast Cancer Research. Dr. McArthur has been working on a Phase 3 clinical trial called KEYNOTE-522, which is testing whether a specific immunotherapy drug improves overall survival for people with high-risk early Triple Negative Breast Cancer. Dr. McArthur, along with her colleagues, are trying to determine if all people with this type of breast cancer truly need the drug, and if not, who would most benefit from taking it.
Metastatic Triple Negative Breast Cancer is one of the most challenging breast cancer subtypes to treat. Recurrence rates can be as high as 40%. This episode covers the role of immunotherapy and antibody-drug conjugates in the advanced space. Once again, targetable receptors are lacking but research is underway!Studies discussed in the episode:KEYNOTE 355ASCENTFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Welcome to the Komen Health Equity Revolution podcast series. Each month, we invite in patients, community organizations, health care providers, researchers and policy advocates to discuss strategies and solutions that drive the health equity revolution forward for multiple populations experiencing breast health inequities. In honor of Black History Month, this Komen Health Equity Revolution episode of the Real Pink podcast takes a deep dive into the unique challenges and disparities Black women face in breast cancer care. Joining me is Komen Scientific Advisory Board member Dr. Lisa Newman, a trailblazing breast surgical oncologist and researcher. In this episode, we'll explore the lack of representation of Black bodies in the medical space and its impact on care and treatment. We'll also discuss culturally responsive care, the transformative role of diverse health care providers, and ways to advocate for yourself as a patient. Let's dive into this important conversation.
ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. The science behind plant-predominant whole-food nutrition, joyful movement, and restorative sleep in enhancing quality of life and promoting recovery. From Evidence to Wellness: Integrative Medicine Approaches for Living Well with Cancer In this enlightening episode, Chef AJ welcomes Dr. Michelle Loy, MD, DipABOIM, DipABLM, DABMA, FAAP, a trailblazing physician in integrative and lifestyle medicine, to discuss how evidence-based, patient-centered, holistic approaches can enhance quality of life for those living with cancer. Dr. Loy delves into her innovative work and shares practical tips for incorporating nutrition, mind-body practices, and other integrative therapies into conventional state-of-the-art cancer care. Dr. Loy is a board-certified physician in Integrative Medicine, Lifestyle Medicine, Medical Acupuncture, and Pediatrics. She serves as an Assistant Professor at Weill Cornell Medicine/NewYork-Presbyterian Hospital, where she provides consultations addressing complex medical issues across all ages. A Harvard graduate with an MD from Cornell, Dr. Loy completed her Integrative Medicine fellowship at Columbia University/Stamford Hospital and earned Medical Acupuncture certification from SUNY Downstate Medical Center and the American Board of Medical Acupuncture. Her dedication to advancing integrative health is reflected in her leadership roles with the AAP Section of Integrative Medicine, American Board of Integrative Medicine, and the American College of Lifestyle Medicine. Insights into the evidence surrounding medical cannabis, culinary mushrooms, herbs, and botanicals for individuals facing cancer, including guidance on their appropriate use. The dangers of cancer misinformation, emphasizing the importance of seeking trusted, credible, evidence-based information, and guidance on discerning reliable resources. Complete list of published works at PubMed at: https://www.ncbi.nlm.nih.gov/myncbi/michelle.loy.1/bibliography/public/ More About Dr. Loy: Dr. Loy is a Lecturer for the Plant-Based Nutrition Certificate Program at Cornell University and serves on the medical advisory board of Plant Powered Metro New York. Her "Shop with the Doc" Culinary Medicine series and Virtual Shared Medical Appointments have been transformative for patients, offering innovative, evidence-based solutions for better health. In her free time, Dr. Loy enjoys exploring farmer's markets, cooking plant-forward meals for her husband and five children, and staying active through running and yoga. Follow Dr. Michelle Loy: Weill Cornell Profile: https://weillcornell.org/michelle-h-loy-md Getting to Know Dr. Loy - Weill Cornell News: https://weillcornell.org/news/getting-to-know-michelle-loy-md-of-integrative-health-and-wellbeing Doximity: https://www.doximity.com/pub/michelle-loy-md
Breast cancer treatment today is becoming more personalized and more precise. Precision medicine is rapidly expanding the options patients have for treating their cancer while helping them maintain a desired quality of life. A common mutation in breast cancer called PIK3CA affects more than 1 in 3 people with breast cancer, making it harder to treat. This mutation often leads to worse outcomes for these patients compared to others. Scientists are now developing new treatments that target this mutation specifically, aiming to reduce side effects and improve treatment outcomes, such as shrinking tumors or preventing disease progression. Today, we are speaking with Dr. Sarah Sammons of Dana-Farber Cancer Institute to explore the exciting new possibilities brought by personalized medicine, including whether it can help slow disease progression and how it can it improve patients' abilities to potentially live more active and productive lives while on treatment.
Descriptions: As part of the IASLC's ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Bashir Abu Aqeel and Dr. Fawzi Abu Rous. The group discusses chemoimmunotherapy in metastatic non-small cell lung cancer.
This is Real Talk, a podcast conversation where we're digging deep into breast cancer and the realities patients and survivors face every day. We're talking openly and honestly about just how difficult breast cancer can be, from being diagnosed to selecting the right treatment plan, to living day to day with metastatic breast cancer, and life after treatment ends. In today's episode, we're talking about the effect treatment has on sexual health and unwanted side effects women face during breast cancer treatment and life thereafter. Joining us today are Jenn Smith and Nisha Jaime. Jenn is 42 years old, and a 3-year breast cancer survivor. She and her husband have been married for 17 years. Nisha is 45 years old and a 1-year breast cancer survivor. She is also married with 3 school-aged children. Both women are learning to live with the impact breast cancer treatment is having on their bodies, their intimacy and their overall wellbeing.
AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer Guest: Jeffrey M Holzbeierlein, MD Outline: Segment #1: Guideline Statement 9-Patients who have not received cisplatin-based NAC and have pT3-4 and/or N= disease at cystectomy should receive adjuvant cisplatin based chemotherapy or adjuvant immunotherapy. Segment #2: Guideline Statement 11-When performing a cystectomy in males the bladder, prostate cand seminal vesicles should be removed (no change) but in females clinicians should consider removal of adjacent reproductive organs based on individual disease characteristics and need to obtain negative margins. Organ sparing procedures in females should be considered based on disease location and characteristics on an individual basis. Segment #3: Guideline Statement 20-When performing bilateral pelvic lymphadenectomy , clinicians should remove, at a minimum, the external and internal iliac and obturator lymph nodes (standard lymphadenectomy). Segment #4: Future Directions Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Holzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO guideline (2017; amended 2020, 2024). J Urol. Published online April 25, 2024. doi:10.1097/JU.0000000000003981 https://www.auajournals.org/doi/10.1097/JU.0000000000003981
On this episode of The CA Media Podcast, Kim and I dives into our podcast without a topic but an emotional subject comes about and we dive into that topic and this thus led to one of the most emotional episodes ever produced. To learn more about Metastatic Breast Cancer, click here: https://www.pennmedicine.org/cancer/types-of-cancer/breast-cancer/types-of-breast-cancer/metastatic-breast-cancer#:~:text=Metastatic%20breast%20cancer%20is%20always,%2C%20bones%2C%20liver%20and%20lungs. We thank Pennmedicine.org for the information To follow Kim: Instagram: https://www.instagram.com/_milkeywayy X: https://x.com/_milkywayy Visionary Minds Public Relations and Media is a supporting sponsor of the CAMedia Podcast Make sure you get your Publicity, Digital Marketing, Writing, Media Consulting Services at visionarymindsny@gmail.com where Tammy Reese is the owner.
As we kick off Black History Month here on Real Pink, we're excited to highlight guests who have been affected by breast cancer and are using their experiences to make an impact. Today's guest advocated for herself to ensure that she was receiving the best, most personalized treatment for her after her diagnosis, and in the process learned the staggering fact that less than 10% of clinical trial participants are members of racial or ethnic communities who often face higher breast cancer or mortality rates. This fueled Tina Pickett to get involved. She is passionate about educating women on early detection, health equity and representation in research and her team was at the top of the fundraising board at her local Race for the Cure.
Tune into the latest episode of Real Pink for a vital conversation about the transformative impact of personalized care, its role in addressing disparities and how it can empower patients in their breast cancer journey. Dr. Ezinne Ihenachor, a diagnostic radiologist and passionate health equity advocate, helps us understand how personalized care can address systemic inequities and improve outcomes for all. Thanks to Merck for supporting the Real Pink Podcast.
Tamoxifen is a medication used to block estrogen, which is needed for some breast tumors to grow. Many survivors are prescribed tamoxifen to lower the risk of having a recurrence of breast cancer, usually after breast cancer surgery, chemotherapy and radiation. Tamoxifen can also be used for breast cancer risk reduction in women who do not have breast cancer but who are at higher risk, which was the case with today's guest. Twenty years after her mother passed away from breast cancer, Colleen Boraca learned she had two conditions that increase her chances of developing breast cancer. At the recommendation of her oncologist, she began her five-year, daily journey with Tamoxifen and is here today to share about her experience, what helped her get through struggles and how she was able to work with her doctor along the way to get the personalized care that was right for her.
© 2020-2025 Ivy Podcast Discovery LLC
